Coherus Oncology (CHRS) Current Assets (2013 - 2026)

Coherus Oncology has disclosed Current Assets across 14 years of filings, most recently posting $206.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $206.0 million, down 33.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $206.0 million (down 33.57% YoY), and the FY2025 annual result was $206.7 million, down 39.49% from the prior year.
• Current Assets came in at $206.0 million for Q1 2026 at Coherus Oncology, roughly flat from $206.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $627.5 million in Q1 2024 to a low of $206.0 million in Q1 2026.
• The 5-year median for Current Assets is $385.5 million (2023), against an average of $404.1 million.
• Across the five-year window, Current Assets jumped 98.62% in 2024 and plunged 50.57% in 2025, its largest moves.
• Coherus Oncology's Current Assets stood at $381.2 million in 2022, then advanced by 24.76% to $475.6 million in 2023, then dropped by 28.18% to $341.6 million in 2024, then slumped by 39.49% to $206.7 million in 2025, then decreased by 0.32% to $206.0 million in 2026.
• The last three Current Assets figures came in at $206.0 million (Q1 2026), $206.7 million (Q4 2025), and $461.0 million (Q3 2025), per Business Quant data.